Chinese Expert Consensus on Clinical Application of Molecular Targeted Drugs for Hepatocellular Carcinoma (2022 edition)

Title: Chinese Expert Consensus on Clinical Application of Molecular Targeted Drugs for Hepatocellular Carcinoma (2022 edition)
Edition: Updated
Classification: Experts consensus
Field: Treatment
Countries and regions: China
Guidelines users: Doctors
Evidence classification method: Table 1. Levels of evidence-based medicine Evidence level Description Ia Evidence stems from results of a meta-analysis of multiple randomized controlled studies Ib Evidence stems from the results of at least one well-designed randomized controlled study IIa Evidence stems from the results of at least one well-designed prospective non-randomized controlled study IIb Evidence was derived from at least one well-designed interventional clinical study III Evidence stems from well-designed non-interventional studies, such as descriptive studies and correlation studies, among others IV Evidence stems from expert committee reports or reports of clinical experience by authoritative experts Table 2. Expert recommendation level Evidence level Description A Good scientific evidence suggests the clear benefit; physicians are advised to apply the medical behavior to patients B Existing evidence indicates that the medical behavior has a moderate benefit beyond its potential risk; the physician may recommend or perform the medical behavior C Existing evidence indicates that the medical behavior may result in fewer benefits or the benefit is not substantial compared with the risk; the physician may selectively advise and implement the medical behavior D Available evidence indicates that the medical behavior does not have benefits or its potential risks outweigh the benefits; the physician should not perform the medical behavior I A lack of scientific evidence is present, or the available evidence cannot be used to evaluate the benefits versus risks of this medical action; physicians should help patients understand the uncertainties that exist about this medical behavior
Development unit: 海军军医大学第三附属医院
Registration time: 2022-06-29
Registration number: IPGRP-2022CN369
Purpose of the guideline: In order to better guide clinical practice, the Chinese Association of Liver Cancer and Chinese Medical Doctor Association has improved and updated the Chinese Expert Consensus on the Clinical Application of Molecular Targeted Drugs for Hepatocellular Carcinoma (2022 edition) for clinicians' reference.